ETS transcription factors and their emerging roles in human cancer.

Cancer can be defined as a genetic disease, resulting as a consequence of multiple events associated with initiation, promotion and metastatic growth. Cancer results from the loss of control of cellular homeostasis. Cell homeostasis is the result of the balance between proliferation and cell death, while cellular transformation can be viewed as a loss of relationship between these events. Oncogenes and tumour suppressor genes act as modulators of cell proliferation, while the balance of apoptotic and anti-apoptotic genes controls cell death. All cancer cells acquire similar sets of functional capacities: (1) independence from mitogenic/growth signals; (2) loss of sensitivity to "anti-growth" signals; (3) evade apoptosis; (4) Neo-angiogenic conversion; (5) release from senescence; and (6) invasiveness and metastasis. One of the goals of molecular biology is to elucidate the mechanisms that contribute to the development and progression of cancer. Such understanding of the molecular basis of cancer will provide new possibilities for: (1) earlier detection as well as better diagnosis and staging of disease with detection of minimal residual disease recurrences and evaluation of response to therapy; (2) prevention; and (3) novel treatment strategies. We feel that increased understanding of ETS-regulated biological pathways will directly impact these areas. ETS proteins are transcription factors that activate or repress the expression of genes that are involved in various biological processes, including cellular proliferation, differentiation, development, transformation and apoptosis. Identification of target genes that are regulated by a specific transcription factor is one of the most critical areas in understanding the molecular mechanisms that control transcription. Furthermore, identification of target gene promoters for normal and oncogenic transcription factors provides insight into the regulation of genes that are involved in control of normal cell growth, and differentiation, as well as provide information critical to understanding cancer development. This review will highlight the current understanding of ETS genes and their role in cancer.

[1]  Michael C. Ostrowski,et al.  Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression , 1992, Molecular and cellular biology.

[2]  C. Hauser,et al.  Ets2 and protein kinase C epsilon are important regulators of parathyroid hormone-related protein expression in MCF-7 breast cancer cells. , 2003, The Biochemical journal.

[3]  T. Wilson,et al.  Ets1 as a marker of malignant potential in gastric carcinoma. , 2003, World journal of gastroenterology.

[4]  A. Sharrocks,et al.  SUMO promotes HDAC-mediated transcriptional repression. , 2004, Molecular cell.

[5]  M. Abe,et al.  Ets‐1 regulates angiogenesis by inducing the expression of urokinase‐type plasminogen activator and matrix metalloproteinase‐1 and the migration of vascular endothelial cells , 1996, Journal of cellular physiology.

[6]  Rameen Beroukhim,et al.  Molecular characterization of the tumor microenvironment in breast cancer. , 2004, Cancer cell.

[7]  I. Sekine,et al.  Expression of the ets-1 proto-oncogene in human breast carcinoma: differential expression with histological grading and growth pattern. , 2005, Histology and histopathology.

[8]  K. Tanaka,et al.  EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. , 1997, The Journal of clinical investigation.

[9]  R. Muise-Helmericks,et al.  Signal transduction and the Ets family of transcription factors , 2000, Oncogene.

[10]  I. Fidler,et al.  Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. , 2002, Journal of the National Cancer Institute.

[11]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[12]  L. Kearney,et al.  The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. , 2001, Cancer research.

[13]  J. Tentler,et al.  ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells , 2004, Oncogene.

[14]  C. Pui.  Medical progress : childhood leukemias , 1995 .

[15]  Wen-Lin Kuo,et al.  ESX: a structurally unique Ets overexpressed early during human breast tumorigenesis , 1997, Oncogene.

[16]  Y. Totsuka,et al.  Antisense E1AF transfection restrains oral cancer invasion by reducing matrix metalloproteinase activities. , 1997, The American journal of pathology.

[17]  N. Takai,et al.  The significance of Elf-1 expression in epithelial ovarian carcinoma. , 2003, International journal of molecular medicine.

[18]  M. Yamakuchi,et al.  PEA3 and AP-1 are required for constitutive IL-8 gene expression in hepatoma cells. , 2000, Biochemical and biophysical research communications.

[19]  K. Fujikawa,et al.  The Ets‐1 and Ets‐2 transcription factors activate the promoters for invasion‐associated urokinase and collagenase genes in response to epidermal growth factor , 1998, International journal of cancer.

[20]  V. Sementchenko,et al.  Pdef expression in human breast cancer is correlated with invasive potential and altered gene expression. , 2003, Cancer research.

[21]  M. Zahurak,et al.  TEL-AML1, expressed from t(12;21) in human acute lymphocytic leukemia, induces acute leukemia in mice. , 2002, Cancer research.

[22]  G. Viglietto,et al.  Induction of ETS-1 and ETS-2 transcription factors is required for thyroid cell transformation. , 2001, Cancer research.

[23]  B. Vandenbunder,et al.  [Transcription factors of the Ets family and morphogenesis of the vascular tree]. , 1999, Journal de la Societe de biologie.

[24]  Yasuhiro Ito,et al.  Expression of ets-1 and ets-2 in colonic neoplasms. , 2002, Anticancer research.

[25]  A. Ullrich,et al.  Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. , 1993, Cancer research.

[26]  S. Baker,et al.  The Splicing Factor U1C Represses EWS/FLI-mediated Transactivation* , 2000, The Journal of Biological Chemistry.

[27]  H. Hasle,et al.  Risks of leukaemia and solid tumours in individuals with Down's syndrome , 2000, The Lancet.

[28]  R. Li,et al.  The p42 variant of ETS1 protein rescues defective Fas-induced apoptosis in colon carcinoma cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  A. Hill,et al.  Prostate-Specific Ets (PSE) factor: a novel marker for detection of metastatic breast cancer in axillary lymph nodes , 2002, British Journal of Cancer.

[30]  R. Cardiff,et al.  Ets2-Dependent Stromal Regulation of Mouse Mammary Tumors , 2003, Molecular and Cellular Biology.

[31]  I. Sekine,et al.  Expression of the ets-1 proto-oncogene in human thyroid tumor. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[32]  R. Lutz,et al.  Highly conserved amino acids in Pax and Ets proteins are required for DNA binding and ternary complex assembly. , 2001, Nucleic acids research.

[33]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[34]  Toshiyuki Yamada,et al.  Molecular biology of the Ets family of transcription factors. , 2003, Gene.

[35]  B. Wasylyk,et al.  Ets ternary complex transcription factors. , 2004, Gene.

[36]  Kathleen Bove,et al.  The transcription factor Ets-1 in breast cancer. , 2005, Frontiers in bioscience : a journal and virtual library.

[37]  K. Shirouzu,et al.  Ets-1 expression in vascular endothelial cells as an angiogenic and prognostic factor in colorectal carcinoma. , 2003, International surgery.

[38]  I. Sekine,et al.  Overexpression of Ets‐1 proto‐oncogene in latent and clinical prostatic carcinomas , 2005, Histopathology.

[39]  M. Greaves,et al.  Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes. , 2001, Blood.

[40]  V. Sementchenko,et al.  Ets target genes: past, present and future , 2000, Oncogene.

[41]  I. Bièche,et al.  Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expression. , 2003, Carcinogenesis.

[42]  K. Mitani,et al.  TEL/AML1 shows dominant-negative effects over TEL as well as AML1. , 2004, Biochemical and biophysical research communications.

[43]  R. Ralhan,et al.  Ets‐1: a plausible marker of invasive potential and lymph node metastasis in human oral squamous cell carcinomas , 1999 .

[44]  A. Mushegian,et al.  The Epithelium-specific ETS Protein EHF/ESE-3 Is a Context-dependent Transcriptional Repressor Downstream of MAPK Signaling Cascades* , 2001, The Journal of Biological Chemistry.

[45]  M. Monden,et al.  ets-1 Expression in Extrahepatic Bile Duct Carcinoma and Cholangiocellular Carcinoma , 2000, Oncology.

[46]  R. Janknecht,et al.  Acetylation-Mediated Transcriptional Activation of the ETS Protein ER81 by p300, P/CAF, and HER2/Neu , 2003, Molecular and Cellular Biology.

[47]  Donald E. Ingber,et al.  How does extracellular matrix control capillary morphogenesis? , 1989, Cell.

[48]  R L Vessella,et al.  Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS‐2 in prostate cancer , 1997, The Prostate.

[49]  R. Cardiff,et al.  A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. , 1999, Cancer research.

[50]  A. Sood,et al.  Prostate epithelium-derived Ets transcription factor mRNA is overexpressed in human breast tumors and is a candidate breast tumor marker and a breast tumor antigen. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  B. Vandenbunder,et al.  c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. , 1992, The American journal of pathology.

[52]  H. Kovar,et al.  Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway. , 2002, Cancer research.

[53]  T. Miki,et al.  Prostate-specific transcription factor hPSE is translated only in normal prostate epithelial cells. , 2000, Cancer research.

[54]  T. Stephenson,et al.  Proteolysis in human breast cancer , 2000, Molecular pathology : MP.

[55]  C. Hauser,et al.  Elevated Expression of Ets2 or Distinct Portions of Ets2 Can Reverse Ras-mediated Cellular Transformation* , 1998, The Journal of Biological Chemistry.

[56]  M. Shibuya,et al.  A cAMP Response Element and an Ets Motif Are Involved in the Transcriptional Regulation of flt-1 Tyrosine Kinase (Vascular Endothelial Growth Factor Receptor 1) Gene* , 1996, The Journal of Biological Chemistry.

[57]  Takahiro Sato,et al.  Ets‐1 and integrin beta3 for lung metastasis from colorectal cancer , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[58]  T. Libermann,et al.  PDEF, a Novel Prostate Epithelium-specific Ets Transcription Factor, Interacts with the Androgen Receptor and Activates Prostate-specific Antigen Gene Expression* , 2000, The Journal of Biological Chemistry.

[59]  Yasuhiro Ito,et al.  Ets-2 overexpression contributes to progression of pancreatic adenocarcinoma. , 2002, Oncology reports.

[60]  A. Nordheim,et al.  Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. , 2003, International journal of oncology.

[61]  P. Riegman,et al.  Translocation (12;22) (p13;q11) in myeloproliferative disorders results in fusion of the ETS-like TEL gene on 12p13 to the MN1 gene on 22q11. , 1995, Oncogene.

[62]  S. Welford,et al.  DNA Binding Domain-independent Pathways Are Involved in EWS/FLI1-mediated Oncogenesis* , 2001, The Journal of Biological Chemistry.

[63]  M. Duffy,et al.  Overexpression of the Ets-1 transcription factor in human breast cancer , 2004, British Journal of Cancer.

[64]  W. Folk,et al.  Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. , 2001, European journal of cancer.

[65]  Lars S Jermiin,et al.  A novel transcription factor, ELF5, belongs to the ELF subfamily of ETS genes and maps to human chromosome 11p13–15, a region subject to LOH and rearrangement in human carcinoma cell lines , 1998, Oncogene.

[66]  T. Nakayama,et al.  Expression of the ets-1 proto-oncogene in human pancreatic carcinoma. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[67]  J. Ghysdael,et al.  Proteins of the ETS family with transcriptional repressor activity , 2000, Oncogene.

[68]  M. Minden,et al.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.

[69]  Y. Taniyama,et al.  Angiogenic Property of Hepatocyte Growth Factor Is Dependent on Upregulation of Essential Transcription Factor for Angiogenesis, ets-1 , 2003, Circulation.

[70]  H. Zhang,et al.  Induction of multiple matrix metalloproteinase genes in human hepatocellular carcinoma by hepatocyte growth factor via a transcription factor Ets-1. , 2003, Hepatology research : the official journal of the Japan Society of Hepatology.

[71]  A. Seth,et al.  The c-ets-1 proto-oncogene has oncogenic activity and is positively autoregulated. , 1990, Oncogene.

[72]  D. Watson,et al.  Ets transcription factors cooperate with Sp1 to activate the human Tenascin-C promoter , 1999, Oncogene.

[73]  V. Sementchenko,et al.  ETS2 function is required to maintain the transformed state of human prostate cancer cells , 1998, Oncogene.

[74]  Y. Furukawa,et al.  Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c , 2003, Oncogene.

[75]  R. Berger,et al.  The t(1;12)(q21;p13) translocation of human acute myeloblastic leukemia results in a TEL-ARNT fusion. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[76]  M. Abe,et al.  ETS‐1 converts endothelial cells to the angiogenic phenotype by inducing the expression of matrix metalloproteinases and integrin β3 , 1999, Journal of cellular physiology.

[77]  T. Graf,et al.  MafB Is an Interaction Partner and Repressor of Ets-1 That Inhibits Erythroid Differentiation , 1996, Cell.

[78]  M. Nakamura,et al.  Hepatocyte growth factor upregulates E1AF that induces oral squamous cell carcinoma cell invasion by activating matrix metalloproteinase genes. , 2000, Carcinogenesis.

[79]  Peter C. Hollenhorst,et al.  Expression profiles frame the promoter specificity dilemma of the ETS family of transcription factors. , 2004, Nucleic acids research.

[80]  M. Roussel,et al.  The MN1-TEL Fusion Protein, Encoded by the Translocation (12;22)(p13;q11) in Myeloid Leukemia, Is a Transcription Factor with Transforming Activity , 2000, Molecular and Cellular Biology.

[81]  M. Monden,et al.  Expression and possible role of ets-1 in hepatocellular carcinoma. , 2000, American journal of clinical pathology.

[82]  Runzhao Li,et al.  EAP1/Daxx interacts with ETS1 and represses transcriptional activation of ETS1 target genes , 2000, Oncogene.

[83]  C. Woodworth,et al.  Altered expression of Erg and Ets-2 transcription factors is associated with genetic changes at 21q22.2-22.3 in immortal and cervical carcinoma cell lines , 1997, Oncogene.

[84]  N. Bhat,et al.  A variant form of ETS1 induces apoptosis in human colon cancer cells , 1997, Oncogene.

[85]  M. Nishimura,et al.  Expression of E1AF/PEA3, an Ets‐related transcription factor in human non‐small‐cell lung cancers: Its relevance in cell motility and invasion , 2001, International journal of cancer.

[86]  J. Aster,et al.  Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. , 2000, The Journal of clinical investigation.

[87]  Hiroyuki Yamamoto,et al.  Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancer. , 2003, Carcinogenesis.

[88]  M. Duterque-Coquillaud,et al.  When Ets transcription factors meet their partners. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[89]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[90]  R. Kudo,et al.  A relationship between Matrix metalloproteinase-1 (MMP-1) promoter polymorphism and cervical cancer progression. , 2003, Cancer letters.

[91]  M. Suico,et al.  The ETS transcription factor MEF is a candidate tumor suppressor gene on the X chromosome. , 2002, Cancer research.

[92]  C. Garvie,et al.  Structural Analysis of the Autoinhibition of Ets-1 and Its Role in Protein Partnerships* , 2002, The Journal of Biological Chemistry.

[93]  J. Tentler,et al.  The epithelial-specific ETS transcription factor ESX/ESE-1/Elf-3 modulates breast cancer-associated gene expression. , 2003, DNA and cell biology.

[94]  A. Seth,et al.  c-ets-2 protooncogene has mitogenic and oncogenic activity. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[95]  M. You,et al.  Molecular profiling of mouse lung tumors: association with tumor progression, lung development, and human lung adenocarcinomas , 2004, Oncogene.

[96]  L. McIntosh,et al.  Secondary structure of the ETS domain places murine Ets-1 in the superfamily of winged helix-turn-helix DNA-binding proteins. , 1994, Biochemistry.

[97]  Marc Aumercier,et al.  ETS-1 Transcription Factor Binds Cooperatively to the Palindromic Head to Head ETS-binding Sites of the Stromelysin-1 Promoter by Counteracting Autoinhibition* , 2002, The Journal of Biological Chemistry.

[98]  Takahiro Ochi,et al.  Transcriptional regulation of osteopontin gene in vivo by PEBP2αA/CBFA1 and ETS1 in the skeletal tissues , 1998, Oncogene.

[99]  C. Hauser,et al.  Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness , 2000, Oncogene.

[100]  F. Cavalli,et al.  Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. , 2004, Nucleic acids research.

[101]  O. Delattre,et al.  EWS/FLI-1 Silencing and Gene Profiling of Ewing Cells Reveal Downstream Oncogenic Pathways and a Crucial Role for Repression of Insulin-Like Growth Factor Binding Protein 3 , 2004, Molecular and Cellular Biology.

[102]  M. Edel.  The ETS-related factor TEL is regulated by angiogenic growth factor VEGF in HUVE-cells. , 1998, Anticancer Research.

[103]  D. Watson,et al.  Amplification and rearrangement of Hu-ets-1 in leukemia and lymphoma with involvement of 11q23. , 1986, Science.

[104]  V. Sementchenko,et al.  SP100 expression modulates ETS1 transcriptional activity and inhibits cell invasion , 2004, Oncogene.

[105]  C. Bloomfield,et al.  Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. , 2004, Blood.

[106]  Todd R. Golub,et al.  Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation , 1994, Cell.

[107]  S. Burdach,et al.  High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). , 2002, Critical reviews in oncology/hematology.

[108]  H. Mugishima,et al.  Detection of chimeric genes in Ewing's sarcoma and its clinical applications. , 2002, Biological & pharmaceutical bulletin.

[109]  W. Muller,et al.  The pea3 subfamily ets genes are required for HER2/Neu-mediated mammary oncogenesis , 2001, Current Biology.

[110]  B. Johansson,et al.  Fusion of the homeobox gene HLXB9 and the ETV6 gene in infant acute myeloid leukemias with the t(7;12)(q36;p13). , 2001, Cancer research.

[111]  H. Chansky,et al.  Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein. , 2001, Cancer research.

[112]  L. Embree,et al.  TLS-ERG Leukemia Fusion Protein Inhibits RNA Splicing Mediated by Serine-Arginine Proteins , 2000, Molecular and Cellular Biology.

[113]  R. Janknecht,et al.  HER2/Neu-mediated activation of the ETS transcription factor ER81 and its target gene MMP-1 , 2001, Oncogene.

[114]  H. Sasaki,et al.  Ets-1 gene expression in patients with thymoma. , 2002, The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi.

[115]  K. Chew,et al.  HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer , 1997, Oncogene.

[116]  M. Biondi,et al.  Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[117]  A. Wellmann,et al.  The Ets‐1 transcription factor is up‐regulated together with MMP 1 and MMP 9 in the stroma of pre‐invasive breast cancer , 2001, The Journal of pathology.

[118]  Thomas N. Sato,et al.  Role of the Ets transcription factors in the regulation of the vascular-specific Tie2 gene. , 1999, Circulation research.

[119]  Runzhao Li,et al.  Regulation of Ets function by protein–protein interactions , 2000, Oncogene.

[120]  N. Bhat,et al.  ETS1 suppresses tumorigenicity of human colon cancer cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[121]  A. Schned,et al.  Loss of heterozygosity on chromosome 11q22-23 in melanoma is associated with retention of the insertion polymorphism in the matrix metalloproteinase-1 promoter. , 2001, The American journal of pathology.

[122]  Shilpi Arora,et al.  Stromelysin 3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous and Cancerous Lesions: Correlation with Microvessel Density, Progression, and Prognosis , 2005, Clinical Cancer Research.

[123]  C. Sweep,et al.  Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer , 2002, Oncogene.

[124]  Runzhao Li,et al.  EAPII interacts with ETS1 and modulates its transcriptional function , 2003, Oncogene.

[125]  Sandya Liyanarachchi,et al.  Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[126]  N. Takai,et al.  Clinical relevance of Elf-1 overexpression in endometrial carcinoma. , 2003, Gynecologic oncology.

[127]  M. Abe,et al.  Role of Transcription Factors in Angiogenesis , 2001 .

[128]  Bernard Vandenbunder,et al.  Expression of an Ets-1 dominant-negative mutant perturbs normal and tumor angiogenesis in a mouse ear model , 2003, Oncogene.

[129]  J. Westermarck,et al.  Regulation of matrix metalloproteinase expression in tumor invasion , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[130]  Tien Hsu,et al.  Ets proteins in biological control and cancer , 2004, Journal of cellular biochemistry.

[131]  B. Wasylyk,et al.  Reversion of Ras transformed cells by Ets transdominant mutants. , 1994, Oncogene.

[132]  Hiroyuki Yamamoto,et al.  Association of ets‐related transcriptional factor E1AF expression with tumour progression and overexpression of MMP‐1 and matrilysin in human colorectal cancer , 2003, The Journal of pathology.

[133]  E. Sprinzak,et al.  Prediction of gene function by genome-scale expression analysis: prostate cancer-associated genes. , 1999, Genome research.

[134]  A. Berner,et al.  The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions , 2004, Clinical & Experimental Metastasis.

[135]  E. Zwarthoff,et al.  The MN1 oncoprotein synergizes with coactivators RAC3 and p300 in RAR-RXR-mediated transcription , 2003, Oncogene.

[136]  C. Hauser,et al.  Changes in the Expression of Many Ets Family Transcription Factors and of Potential Target Genes in Normal Mammary Tissue and Tumors* , 2004, Journal of Biological Chemistry.

[137]  M. Nishi,et al.  A tumor profile in Down syndrome. , 1998, American journal of medical genetics.

[138]  P. Albers,et al.  Angiogenetic protooncogene ets-1 induced neovascularization is involved in the metastatic process of testicular germ cell tumors. , 2003, European urology.

[139]  R. Sood,et al.  Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[140]  G van den Engh,et al.  Cell-cell interaction in prostate gene regulation and cytodifferentiation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[141]  G. Nucifora,et al.  Small ubiquitin-like modifier conjugation regulates nuclear export of TEL, a putative tumor suppressor , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[142]  Christopher T Denny,et al.  Biology of EWS/ETS fusions in Ewing's family tumors , 2001, Oncogene.

[143]  A. Wellmann,et al.  Stromal expression of invasion‐promoting, matrix‐degrading proteases MMP‐1 and ‐9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers , 2003, International journal of cancer.

[144]  W. Greco,et al.  Prostate derived Ets transcription factor shows better tumor-association than other cancer-associated molecules. , 2004, Oncology reports.

[145]  Y. Hayashi,et al.  An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation. , 1994, Cancer research.

[146]  S. Shibata,et al.  Ets-1 transcription factor-mediated urokinase-type plasminogen activator expression and invasion in glioma cells stimulated by serum and basic fibroblast growth factors. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[147]  A. Seth,et al.  ETS transcription factors and targets in tumour invasion, angiogenesis and bone metastasis , 2001, Expert opinion on therapeutic targets.

[148]  Mina J Bissell,et al.  The organizing principle: microenvironmental influences in the normal and malignant breast. , 2002, Differentiation; research in biological diversity.

[149]  S. Baker,et al.  EWS/FLI Alters 5′-Splice Site Selection* , 2001, The Journal of Biological Chemistry.

[150]  E. McDermott,et al.  Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer , 2005, Clinical Cancer Research.

[151]  Y. Maehara,et al.  Concurrent overexpression of ETS‐1 and C‐met correlates with a phenotype of high cellular motility in human esophageal cancer , 2002, International journal of cancer.

[152]  J. Lautenberger,et al.  Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. , 1997, Cancer research.

[153]  P. Oettgen,et al.  Role of Ets factors in the activity and endothelial cell specificity of the mouse Tie gene promoter , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[154]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[155]  O. Wiestler,et al.  Expression of the Ets-1 transcription factor in human astrocytomas is associated with Fms-like tyrosine kinase-1 (Flt-1)/vascular endothelial growth factor receptor-1 synthesis and neoangiogenesis. , 1999, Cancer research.

[156]  A. Hart,et al.  Human ERG is a proto-oncogene with mitogenic and transforming activity. , 1995, Oncogene.

[157]  H. Sasaki,et al.  Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. , 2001, The Journal of surgical research.

[158]  Jürgen Dittmer,et al.  The Biology of the Ets1 Proto-Oncogene , 2003, Molecular Cancer.

[159]  G. Thomas,et al.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours , 1992, Nature.

[160]  Martin Rosenberg,et al.  A novel epithelial-expressed ETS gene, ELF3: human and murine cDNA sequences, murine genomic organization, human mapping to 1q32.2 and expression in tissues and cancer , 1997, Oncogene.

[161]  J. Hassell,et al.  Function of PEA3 Ets Transcription Factors in Mammary Gland Development and Oncogenesis , 2003, Journal of Mammary Gland Biology and Neoplasia.

[162]  F. Révillion,et al.  Prognostic Value of ERM Gene Expression in Human Primary Breast Cancers , 2004, Clinical Cancer Research.

[163]  V. Sementchenko,et al.  Ets1 Is an Effector of the Transforming Growth Factor β (TGF-β) Signaling Pathway and an Antagonist of the Profibrotic Effects of TGF-β* , 2002, The Journal of Biological Chemistry.

[164]  A. Maggio,et al.  Amplification of ETS2 oncogene in acute nonlymphoblastic leukemia with t(6;21;18). , 1992, Cancer genetics and cytogenetics.

[165]  N. Takai,et al.  c-Ets1 is a promising marker in epithelial ovarian cancer. , 2002, International journal of molecular medicine.

[166]  M. Kaplan,et al.  Partially Unspliced and Fully Spliced ELF3 mRNA, Including a New Alu Element in Human Breast Cancer , 2004, Breast Cancer Research and Treatment.

[167]  M. Trojanowska.  Ets factors and regulation of the extracellular matrix , 2000, Oncogene.